Physician profile
Derek A Ott
NPI 1710920111
$329,144.29
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $28K · 2021: $73K · 2022: $82K · 2023: $80K · 2024: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Honoraria: $16K · Consulting Fee: $14K · Travel and Lodging: $9,499 · Food and Beverage: $7,926 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,169 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,105.00 |
| Honoraria | $15,650.00 |
| Consulting Fee | $14,026.00 |
| Travel and Lodging | $9,499.00 |
| Food and Beverage | $7,925.81 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,168.75 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $105,303.41 | 2019-2024 | Qelbree, Qelbree |
| Corium, LLC | $55,017.74 | 2021-2024 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $46,459.07 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $44,719.05 | 2019-2023 | Dyanavel Xr, Quillichew Er, Quillivant |
| Allergan, INC. | $12,602.74 | 2019-2020 | |
| Abbvie INC. | $12,391.36 | 2021-2024 | |
| Alkermes, INC. | $12,146.92 | 2019-2024 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $9,062.05 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $8,146.04 | 2020-2024 | Caplyta |
| Noven Pharmaceuticals, INC. | $7,403.12 | 2024 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $2,920.37 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $2,593.00 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $1,757.00 | 2019-2024 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,635.10 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,597.14 | 2019-2024 | Rexulti, Nuedexta, Abilify Maintena |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,531.48 | 2019-2024 | Rexulti |
| Neos Therapeutics, Lp | $1,265.66 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $421.16 | 2019-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $377.08 | 2022-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $312.15 | 2019-2023 | Austedo Xr, Uzedy |
| Harmony Biosciences LLC | $261.29 | 2022-2023 | Wakix |
| Adlon Therapeutics L.P. | $249.49 | 2019-2021 | |
| Shire North American Group INC | $193.52 | 2019 | |
| Jazz Pharmaceuticals INC. | $182.70 | 2019 | |
| Idorsia Pharmaceuticals US INC | $156.25 | 2022-2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $138.26 | 2019-2024 | Relexxii |
| Arbor Pharmaceuticals, INC. | $136.33 | 2019-2022 | |
| Noven Therapeutics, LLC | $112.15 | 2023-2024 | Xelstrym, Secuado |
| Sumitomo Pharma America, INC. | $26.59 | 2023 | Latuda |
| Aytu Biopharma, INC. | $26.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.